Inotuzumab ozogamicin (Besponsa) is a targeted drug used for the treatment of relapsed or refractory CD22-positive precursor B-cell acute lymphoblastic leukemia.

How to Purchase Inotuzumab Ozogamicin (Besponsa)

Overseas Purchase

Patients may choose to consult and purchase the drug at hospital pharmacies or legitimate drugstores in countries or regions where inotuzumab ozogamicin has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase Through Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchasing Inotuzumab Ozogamicin (Besponsa)

In-Hospital Treatment Requirement

The first administration of this drug and each subsequent cycle of administration are usually recommended to be conducted in a hospital setting.

This is because the drug requires intravenous infusion, and severe infusion-related reactions may occur, which need to be monitored and managed in a medical environment.

Vigilance Against Risks of Severe Adverse Reactions

Hepatotoxicity (especially hepatic veno-occlusive disease, VOD): It is one of the most dangerous complications. Patients must pay close attention to symptoms such as jaundice (yellowing of the skin or eyes), right upper abdominal pain, rapid weight gain, and abdominal distension (ascites); once these symptoms appear, they should report to the doctor immediately.

Myelosuppression: The drug can cause a decrease in platelets, white blood cells, and red blood cells, increasing the risk of severe infection and bleeding.

Other risks: Also include infusion reactions (e.g., fever, chills, dyspnea) and QT interval prolongation. Before drug administration, premedications (such as corticosteroids and antihistamines) need to be used to reduce the risk of certain reactions.

Warnings for Fertility and Lactation

This drug poses potential hazards to the fetus.

Men and women of childbearing age must use effective contraceptive measures during treatment and for a certain period after drug discontinuation (8 months after the last dose for women, and 5 months after the last dose for men).

Lactating women should discontinue breastfeeding during this period.

How to Identify the Authenticity of the Drug

Outer Packaging

The outer packaging should be intact, clean, clearly printed, and free of damage or tampering marks.

Check whether the manufacturer information is "Pfizer" or its subsidiaries.

Drug Form

Inotuzumab ozogamicin is a white to off-white lyophilized powder.

If the substance in the vial is abnormally colored, caked, melted, or contains unintended particles, the drug’s authenticity should be immediately questioned and its use refused.